Gapping up
In reaction to strong earnings/guidance: TUBE +22.9%, ICUI +15.9%, CALL +11.7%, NSPH +10.8%, NVAX +10%, SYMC +7.2%, (also confirms the sale of Veritas to The Carlyle Group (CG) for $8 bln in cash, expects to receive ~$6.3 bln in net cash proceeds, Raises stock repurchase program to $2.6 bln), MNGA +6.9%, HALO +6.6%, REN +6.4%, SHAK +5.3%, ADRO+5.3%, AMBC +4.8%, SFXE +3.8%, MODN +3.6%, ARCO +3.6%, RAX +3.2%, PFSW +3.2%, LYV +2.9%, MACK +1.8%, JASO +1.8%, HCHC +1.7%, ANTH +1.4%, FSIC +1.2%, TWER +0.6%, WYY +0.6%
M&A news: YDLE +37.1% (Yodlee to be acquired by Envestnet (ENV) for $18.88/share, or ~$660 mln; expected to close in Q4 2015), TEX +22.8% (Terex and and Konecranes to combine in all-stock merger of equals), NTLS +22.4% (Shenandoah Telecom enters into a definitive agreement to acquire NTELOS Holdings Corp (NTLS) for $9.25/share in cash), SYA +6.7% (to be acquired by Sumitomo Life Insurance for $32.50/share in cash, or ~$3.8 bln)
Select mining stocks trading higher: KGC +3.4%, AUY +2.4%, GG +1.3%, GDX +1%, GOLD +0.9%, NEM +0.8%
Other news: AQXP +51% (cont strength), AEZS +18.8% (announces that the independent DSMB for its pivotal Phase 3 ZoptEC, will complete a second interim efficacy and safety analysis of the compound in October, 2015), TINY +16.5% (reported June 30, 2015 net asset value of $3.34 per share; Board authorized $2.5 mln stock repurchase program), NVAX +8.6% (announces positive top-line data from a Phase 2 clinical trial of its RSV F vaccine), NBG +6.1% (reports that Greece and creditors have made a deal), GOOG +5.2% (Google announces plans for new Operating Structure; to create a new company called Alphabet; Alphabet Inc. will replace Google Inc. as the publicly-traded entity and all shares of Google will automatically convert into the same number of shares of Alphabet, with all of the same rights ), DPLO +3% (to offer AstraZeneca's (AZN) IRESSA, recently approved by the FDA as a first-line therapy for a specific type of metastatic non-small cell lung cancer), RLYP +2.2% ( enters into a two-year detailing agreement with Sanofi (SNY) for Patiromer), VLTC +1.2% (cont strength)
Analyst comments: KATE +2.1% (added to Focus List at Citigroup), ECHO +0.8% (upgraded to Outperform from Neutral at Macquarie), XL +0.7% (added to Conviction Buy List at Goldman
)
In reaction to strong earnings/guidance: TUBE +22.9%, ICUI +15.9%, CALL +11.7%, NSPH +10.8%, NVAX +10%, SYMC +7.2%, (also confirms the sale of Veritas to The Carlyle Group (CG) for $8 bln in cash, expects to receive ~$6.3 bln in net cash proceeds, Raises stock repurchase program to $2.6 bln), MNGA +6.9%, HALO +6.6%, REN +6.4%, SHAK +5.3%, ADRO+5.3%, AMBC +4.8%, SFXE +3.8%, MODN +3.6%, ARCO +3.6%, RAX +3.2%, PFSW +3.2%, LYV +2.9%, MACK +1.8%, JASO +1.8%, HCHC +1.7%, ANTH +1.4%, FSIC +1.2%, TWER +0.6%, WYY +0.6%
M&A news: YDLE +37.1% (Yodlee to be acquired by Envestnet (ENV) for $18.88/share, or ~$660 mln; expected to close in Q4 2015), TEX +22.8% (Terex and and Konecranes to combine in all-stock merger of equals), NTLS +22.4% (Shenandoah Telecom enters into a definitive agreement to acquire NTELOS Holdings Corp (NTLS) for $9.25/share in cash), SYA +6.7% (to be acquired by Sumitomo Life Insurance for $32.50/share in cash, or ~$3.8 bln)
Select mining stocks trading higher: KGC +3.4%, AUY +2.4%, GG +1.3%, GDX +1%, GOLD +0.9%, NEM +0.8%
Other news: AQXP +51% (cont strength), AEZS +18.8% (announces that the independent DSMB for its pivotal Phase 3 ZoptEC, will complete a second interim efficacy and safety analysis of the compound in October, 2015), TINY +16.5% (reported June 30, 2015 net asset value of $3.34 per share; Board authorized $2.5 mln stock repurchase program), NVAX +8.6% (announces positive top-line data from a Phase 2 clinical trial of its RSV F vaccine), NBG +6.1% (reports that Greece and creditors have made a deal), GOOG +5.2% (Google announces plans for new Operating Structure; to create a new company called Alphabet; Alphabet Inc. will replace Google Inc. as the publicly-traded entity and all shares of Google will automatically convert into the same number of shares of Alphabet, with all of the same rights ), DPLO +3% (to offer AstraZeneca's (AZN) IRESSA, recently approved by the FDA as a first-line therapy for a specific type of metastatic non-small cell lung cancer), RLYP +2.2% ( enters into a two-year detailing agreement with Sanofi (SNY) for Patiromer), VLTC +1.2% (cont strength)
Analyst comments: KATE +2.1% (added to Focus List at Citigroup), ECHO +0.8% (upgraded to Outperform from Neutral at Macquarie), XL +0.7% (added to Conviction Buy List at Goldman
)